Merck KGaA Overcomes Ukraine Disruption To Keep MS Frontrunner On Track
FDA Has Approved Trial Adaptations
The German group is optimistic evobrutinib can be a blockbuster in multiple sclerosis and has adapted its pivotal trial to cope with disruption caused by the war in Ukraine.
